A global ranking approach to end points in trials of mechanical circulatory support devices

被引:36
作者
Felker, G. Michael [1 ,2 ]
Anstrom, Kevin J. [1 ]
Rogers, Joseph G. [1 ,2 ]
机构
[1] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27705 USA
[2] Duke Univ, Sch Med, Div Cardiovasc Med, Durham, NC 27705 USA
关键词
clinical trials; ventricular assist device; end points; heart failure;
D O I
10.1016/j.cardfail.2008.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although previous studies of mechanical circulatory support devices (MCSDs) have used all-cause mortality as a primary end point, trends in device technology and implementation will increasingly necessitate the use of composite end points for MCSD studies. The ideal composite end point for studies of MCSDs is uncertain. Methods and Results: We reviewed the advantages and disadvantages of traditional composite end points in MCSD studies from both a clinical and statistical perspective. Although composite end points may increase statistical power, they also introduce potential problems in interpretation of data, and in some situations may interpret a given clinical course in ways very different than it would be viewed by patients or providers. A global ranking end point, which ranks various aspects of the clinical course based on a prespecified hierarchical ranking system, may provide many of the advantages of composite end points while avoiding many of the pitfalls. One version of such an end point for use in MCSD studies is proposed. Conclusions: Use of a global ranking end point for incorporating various components of the clinical course into a single end point retains much of the benefit of composite end points while avoiding many of the limitations associated with the use of composites. Adoption of such end points may facilitate the development of MCSD therapy.
引用
收藏
页码:368 / 372
页数:5
相关论文
共 20 条
[1]   Bridge to life - Cardiac mechanical support [J].
Baughman, Kenneth L. ;
Jarcho, John A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :846-849
[2]   LEFT-VENTRICULAR EJECTION FRACTION MAY NOT BE USEFUL AS AN END-POINT OF THROMBOLYTIC THERAPY COMPARATIVE TRIALS [J].
CALIFF, RM ;
HARRELSONWOODLIEF, L ;
TOPOL, EJ .
CIRCULATION, 1990, 82 (05) :1847-1853
[3]  
Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt
[4]  
1341::AID-SIM129&gt
[5]  
3.0.CO
[6]  
2-7
[7]   Worst-rank score analysis with informatively missing observations in clinical trials [J].
Lachin, JM .
CONTROLLED CLINICAL TRIALS, 1999, 20 (05) :408-422
[8]   Magnesium for neuroprotection after traumatic brain injury [J].
Maas, Andrew I. R. ;
Murray, Gordon D. .
LANCET NEUROLOGY, 2007, 6 (01) :20-21
[9]   Power calculation for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome [J].
McMahon, RP ;
Harrell, FE .
CONTROLLED CLINICAL TRIALS, 2000, 21 (04) :305-312
[10]   Use of a continuous-flow device in patients awaiting heart transplantation [J].
Miller, Leslie W. ;
Pagani, Francis D. ;
Russell, Stuart D. ;
John, Ranjit ;
Boyle, Andrew J. ;
Aaronson, Keith D. ;
Conte, John V. ;
Naka, Yoshifumi ;
Mancini, Donna ;
Delgado, Reynolds M. ;
MacGillivray, Thomas E. ;
Farrar, David J. ;
Frazier, O. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :885-896